Antianemic Agent - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Antianemic Agent

The Experts below are selected from a list of 18 Experts worldwide ranked by ideXlab platform

Antianemic Agent – Free Register to Access Experts & Abstracts

P. Revill – One of the best experts on this subject based on the ideXlab platform.

  • CERA: Antianemic Agent erythropoietin receptor agonist
    Drugs of The Future, 2006
    Co-Authors: P. Revill

    Abstract:

    CERA (continuous erythropoietin receptor activator) is an erythropoietin (EPO)-stimulating Agent developed for the treatment of anemia related to chronic kidney disease (CKD) and cancer. It is a third-generation pegylated recombinant human EPO with a longer elimination half-life than previous molecules (epoetin and darbepoetin alfa), and with reduced immunogenicity. Preclinical and clinical studies indicate that CERA may be as effective as the first- and second-generation EPOs in treating anemia, but require less frequent dosing. It is undergoing regulatory review for anemia associated with CKD and phase II trials are under way in cancer patients with chemotherapy-induced anemia.

Cai Yafei – One of the best experts on this subject based on the ideXlab platform.

  • Salubrinal, a novel inhibitor of eIF‐2α dephosphorylation, promotes erythropoiesis at early stage targeted by ufmylation pathway
    Journal of cellular physiology, 2019
    Co-Authors: Fanghui Chen, Chaofeng Xing, Wei Zhang, Cai Yafei

    Abstract:

    Ufmylation was proved to play a crucial role in hematopoietic stem cell (HSC) survival and erythroid differentiation, ufmylation deficiency induces acute anemia and lethality of embryos and adults in mouse models. To screen some compounds to rescue phenotypes induced by gene deletion, in this study, we used DDRGK1F/F ; CreERT2 conditional knockout mice, DDRGK1F/F ; CreERT2 bone marrow (BM) and fetal liver cells (FL), Uba5, and DDRGK1 knockdown human CD34 cell in vivo and in vitro, we found salubrinal, a novel inhibitor of eIF-2α dephosphorylation, promoted erythropoiesis at early stage, and partly rescued the acute anemia induce by DDRGK1 deficiency through upregulation of ufmylation and erythroid transcription factors. In phenylhydrazine (PHZ)-induced hemolytic anemia mice, interestingly, salubrinal could significantly improve hemocrit and red blood cell (RBC) indices of the mice treated with PHZ via upregulation of ufmylation. Its novel function was verified to attenuate unfolded protein response (UPR) and cell death programs, and to keep endoplasmic reticulum (ER) homeostasis in HSCs. Taken together results, it suggested that salubrinal may be a promising Antianemic Agent targeted by ufmylation.

Fanghui Chen – One of the best experts on this subject based on the ideXlab platform.

  • Salubrinal, a novel inhibitor of eIF‐2α dephosphorylation, promotes erythropoiesis at early stage targeted by ufmylation pathway
    Journal of cellular physiology, 2019
    Co-Authors: Fanghui Chen, Chaofeng Xing, Wei Zhang, Cai Yafei

    Abstract:

    Ufmylation was proved to play a crucial role in hematopoietic stem cell (HSC) survival and erythroid differentiation, ufmylation deficiency induces acute anemia and lethality of embryos and adults in mouse models. To screen some compounds to rescue phenotypes induced by gene deletion, in this study, we used DDRGK1F/F ; CreERT2 conditional knockout mice, DDRGK1F/F ; CreERT2 bone marrow (BM) and fetal liver cells (FL), Uba5, and DDRGK1 knockdown human CD34 cell in vivo and in vitro, we found salubrinal, a novel inhibitor of eIF-2α dephosphorylation, promoted erythropoiesis at early stage, and partly rescued the acute anemia induce by DDRGK1 deficiency through upregulation of ufmylation and erythroid transcription factors. In phenylhydrazine (PHZ)-induced hemolytic anemia mice, interestingly, salubrinal could significantly improve hemocrit and red blood cell (RBC) indices of the mice treated with PHZ via upregulation of ufmylation. Its novel function was verified to attenuate unfolded protein response (UPR) and cell death programs, and to keep endoplasmic reticulum (ER) homeostasis in HSCs. Taken together results, it suggested that salubrinal may be a promising Antianemic Agent targeted by ufmylation.